The visual symptoms first noted by individuals with age-related macular degeneration (AMD) often include difficulties adjusting to dim lighting and with driving at night.
1–7 These symptoms typically occur in the absence of decreased visual acuity. Such changes in rod-mediated visual function are consistent with histologic evaluations of donor autopsy eyes showing early and preferential loss of rod over cone photoreceptors, a pattern that persists over the course of the disease.
8,9 Psychophysical measures of rod-mediated function include scotopic sensitivity, which measures the maximum light sensitivity of the fully dark-adapted retina, and dark adaptation (DA), the rate of recovery of retinal sensitivity after exposure to an intense light.
Both scotopic sensitivity and DA worsen with advanced age but are most affected by the presence of disease (AMD); of the two parameters, DA is most significantly affected in AMD.
9–16 Because slower DA reflects a disease-relevant functional change that parallels subjective visual symptoms under low luminance conditions,
7,17 DA has been considered as a potential functional biomarker in intermediate AMD.
6,16,18 In addition, the measurement of scotopic thresholds provides data on rod function that is complementary to DA measurements; investigating both parameters increases our understanding of changes in rod-mediated function in AMD.
19
Historically, scotopic sensitivity has been measured using modified versions of commercial perimeters (e.g., the Tubingen perimeter,
20 Humphrey perimeter,
10,21,22 and Octopus perimeter
23). In recent years, an increasing number of commercial instruments have become available, including the MP-1S (Nidek Technologies, Padova, Italy),
24,25 the scotopic Macular Integrity Assessment (CenterVue, Padova, Italy),
26,27 the MonCvONE (MetroVision, Perenchies, France), and the Medmont Dark-Adapted Chromatic Perimeter (DACP) (Medmont, Nunawading, Australia).
28,29 There is, however, a relative paucity of test–retest variability data for scotopic measurements with these devices, with literature surveys revealing a single study each for AMD
28 and retinitis pigmentosa
29 with the Medmont DACP, a single study of retinitis pigmentosa with a modified Humphrey perimeter,
30 and single studies of healthy volunteers, maculopathy and AMD patients with the scotopic Macular Integrity Assessment.
26,27,31
Data on the test–retest variability of DA parameters are also scarce, with a single study of AMD patients with a prototype of the AdaptDx (MacuLogix, Harrisburg, PA)
16 and one study of healthy volunteers with the Goldmann–Weekers adaptometer,
32 which is no longer in production.
Scotopic thresholds and DA are altered along a steep gradient across retinal eccentricity from the fovea in AMD, with the largest deficits occurring nearest the fovea.
19,28,33 By quantifying the different spatial variations in both scotopic threshold and DA with the Medmont DACP, we were able to further define rod function phenotypes in AMD. A detailed understanding of test–retest repeatability metrics for both scotopic sensitivity and DA, at different eccentricities from the fovea, is essential to the design of future studies and trials using these measures.